Latest News Archive

Please select Category, Year, and then Month to display items
Years
2019 2020 2021 2024
Previous Archive
18 July 2019 | Story Julian Roup | Photo Leonie Bolleurs
Clear glass
UFS researchers Lucas Erasmus (left), researcher in the UFS Department of Physics and Prof Hendrik Swart, senior professor in the UFS Department of Physics and SARChI chair (South African Research Chairs Initiative) in Solid State Luminescent and Advanced Materials, with the equipment used for the ground-breaking research.

A revolutionary new type of window glass – in effect a transparent solar panel - is the objective of joint research being done by the University of the Free State (UFS) in South Africa and Ghent University in Belgium. 

A working model has been created which proves the viability of the process which now needs to be refined, made more efficient and brought to the market. It is hoped to achieve this within a decade.

This new product will have the capacity to revolutionise the generation of power cheaply from the sun to power homes, factories and cities in a new clean way.

Academics from the UFS, Prof Hendrik Swart and Lucas Erasmus are doing joint research with Ghent University in Belgium, to find solutions for energy production. 

The two universities entered into an agreement recently for this research into electricity generation. The research is driven by the UFS and was prompted by ever-rising electricity prices and growing demand for electricity production. South Africa lives with constant power outages which leaves people stuck in lifts and facing chaos on the roads as traffic lights cut out. Many people who can afford them now rely on generators.

Prof Hendrik Swart, senior professor in the Department of Physics at the University of the Free State and SARChI chair (South African Research Chairs Initiative) in Solid State Luminescent and Advanced Materials, says: “An innovation like this which can help to replace traditional means of carbon based fuel for power generation in our daily lives would be hugely welcome.”

Swart explains the main objective of the research: “The idea is to develop glass that is transparent to visible light, just like the glass you find in the windows of buildings, motor vehicles and mobile electronic devices. However, by incorporating the right phosphor materials inside the glass, the light from the sun that is invisible to the human eye (ultraviolet and infrared light) can be collected, converted and concentrated to the sides of the glass panel where solar panels can be mounted. 

This invisible light can then be used to generate electricity to power buildings, vehicles and electronic devices. The goal is therefore to create a type of transparent solar panel.”

Swart says this technology can be implemented in the building environment to meet the energy demands of the people inside the buildings. “The technology is also good news for the 4.7 billion cell phone users in the world, as it can be implemented in the screens of cell phones, where the sun or the ambient light of a room can be used to power the device without affecting its appearance,” he said.

Another possible application is in electric cars, where the windows can be used to help power the vehicle.

Lucas Erasmus who is working with Prof Swart adds: “We are also looking at implementing this idea into hard, durable plastics that can act as a replacement for zinc roofs. This will allow visible diffused light to enter housing and the invisible light can then be used to generate electricity. The device also concentrates the light from a large area to the small area on the sides where the solar panels are placed; therefore, reducing the number of solar panels needed and in return, reducing the cost.”

It is envisaged that the technology will take about a decade to refine and implement. This study is currently on-going, and UFS are experimenting and testing different materials in order to optimise the device in the laboratory. It then needs to be upscaled in order to test it in the field. “It is truly the technology of the future,” says 
Erasmus.

The UFS envisages that the end result of this research will provide an attractive solution to address the energy demands of buildings, electric motor vehicles and mobile electronics without affecting their appearance. 

According to Swart, the agreement entails a joint doctoral degree in which both universities will supervise the project and the awarding of the doctorate. Lucas Erasmus, a student at the UFS, has been tasked with the assignment to conduct research at both institutions.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept